Nantahala Capital Management, LLC holds a diversified book of 130 stocks worth $1.6B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Vaxcyte Inc and trimmed Hilton Grand Vacations Inc. Their largest long position is Bancorp Inc at 5% of the equity book. They also disclosed $613.4M in put options (a bearish bet) and $500.7M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1472322/holdings"
Use Arkolith to show Nantahala Capital Management, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
96% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Bancorp Inc Del COM | $74.2M | 1.38M | 4.6% | ▲+29% Added · +309K sh | |
| 2 | Hilton Grand Vacations Inc COM | $59.2M | 1.51M | 3.7% | ▼−3.1% Reduced · −48K sh | |
| 3 | Soleno Therapeutics Inc COM | $58.4M | 1.74M | 3.6% | ▲+33% Added · +430K sh | |
| 4 | Bioventus Inc COM CL A | $55.9M | 6.12M | 3.5% | ▲+1.2% Added · +75K sh | |
| 5 | Peloton Interactive Inc CL A COM | $51.5M | 12.00M | 3.2% | ▲+102% Added · +6.1M sh | |
| 6 | Establishment Labs Hldgs Inc COM | $47.3M | 833.0K | 3.0% | ▼−16% Reduced · −155K sh | |
| 7 | Savara Inc COM | $40.1M | 7.34M | 2.5% | —Held | |
| 8 | Xtant Med Hldgs Inc COM NEW | $38.2M | 68.39M | 2.4% | —Held | |
| 9 | Gogo Inc COM | $35.7M | 8.88M | 2.2% | ▲+31% Added · +2.1M sh | |
| 10 | Amneal Pharmaceuticals Inc COM STK CL A | $35.4M | 2.84M | 2.2% | ▲+16% Added · +397K sh | |
| 11 | Anteris Technologies Global COM | $30.7M | 5.53M | 1.9% | ▲+119% Added · +3.0M sh | |
| 12 | Eton Pharmaceuticals Inc COM | $29.0M | 1.18M | 1.8% | —Held | |
| 13 | Evolus Inc COM | $26.2M | 6.38M | 1.6% | ▲+9.6% Added · +556K sh | |
| 14 | Tango Therapeutics Inc COM | $26.2M | 1.25M | 1.6% | ▼−65% Reduced · −2.3M sh | |
| 15 | LB Pharmaceuticals Inc COM SHS | $26.0M | 1.05M | 1.6% | ▲+56% Added · +378K sh | |
| 16 | Fox Factory Hldg Corp COM | $24.5M | 1.49M | 1.5% | ▼−32% Reduced · −700K sh | |
| 17 | Mineralys Therapeutics Inc COM | $24.3M | 895.5K | 1.5% | ▲+690% Added · +782K sh | |
| 18 | Zevra Therapeutics Inc COM NEW | $23.5M | 2.52M | 1.5% | ▲+42% Added · +750K sh | |
| 19 | Fulcrum Therapeutics Inc COM | $23.4M | 3.05M | 1.5% | ▼−29% Reduced · −1.2M sh | |
| 20 | Fossil Group Inc COM | $23.3M | 5.40M | 1.5% | ▲+6.7% Added · +340K sh | |
| 21 | Ridenow Group Inc COM CL B | $23.1M | 3.27M | 1.4% | —Held | |
| 22 | Abeona Therapeutics Inc COM NEW | $22.5M | 5.01M | 1.4% | ▲+1.0% Added · +50K sh | |
| 23 | Camping World Hldgs Inc CL A | $22.3M | 3.26M | 1.4% | ▲+208% Added · +2.2M sh | |
| 24 | Adc Therapeutics Sa SHS | $21.0M | 5.60M | 1.3% | ▲+2.2% Added · +122K sh | |
| 25 | Titan Machy Inc COM | $21.0M | 1.25M | 1.3% | ▲+2.8% Added · +34K sh | |
| 26 | Herbalife Ltd COM SHS | $19.9M | 1.35M | 1.2% | ▲+54% Added · +472K sh | |
| 27 | Imax Corp COM | $19.6M | 515.6K | 1.2% | ▲+8.1% Added · +38K sh | |
| 28 | Verastem Inc COM NEW | $19.0M | 3.58M | 1.2% | ▲+676% Added · +3.1M sh | |
| 29 | Biocryst Pharmaceuticals Inc COM | $18.9M | 1.99M | 1.2% | ▲+47% Added · +631K sh | |
| 30 | Avalo Therapeutics Inc COM NEW | $18.4M | 1.24M | 1.2% | —Held | |
| 31 | RMR Group Inc CL A | $17.8M | 1.15M | 1.1% | —Held | |
| 32 | Rayonier Advanced Matls Inc COM | $17.7M | 1.60M | 1.1% | ▼−11% Reduced · −200K sh | |
| 33 | Geron Corp COM | $16.7M | 11.22M | 1.0% | ▲+24% Added · +2.2M sh | |
| 34 | Benitec Biopharma Inc COM NEW | $15.3M | 1.44M | 1.0% | ▲+39% Added · +400K sh | |
| 35 | Abivax Sa SPONSORED ADS | $15.3M | 137.2K | 1.0% | ▼−10% Reduced · −16K sh | |
| 36 | Integer Hldgs Corp COM | $15.1M | 172.0K | 0.9% | ▲+69% Added · +70K sh | |
| 37 | Keros Therapeutics Inc COM | $15.0M | 1.36M | 0.9% | ▲+277% Added · +1.0M sh | |
| 38 | Jack In The Box Inc COM | $14.9M | 1.54M | 0.9% | ▲+78% Added · +677K sh | |
| 39 | Jefferson Capital Inc COM | $14.4M | 750.0K | 0.9% | ▲+25% Added · +150K sh | |
| 40 | Aura Biosciences Inc COM | $14.2M | 2.12M | 0.9% | —Held | |
| 41 | Usana Health Sciences Inc COM | $14.2M | 810.1K | 0.9% | ▲+38% Added · +225K sh | |
| 42 | Vaxcyte Inc COM | $13.9M | 238.7K | 0.9% | ▲New New position | |
| 43 | Mimedx Group Inc COM | $13.4M | 3.40M | 0.8% | ▲+41% Added · +981K sh | |
| 44 | Assertio Holdings Inc COM NEW | $13.2M | 692.3K | 0.8% | ▲+18% Added · +105K sh | |
| 45 | Distribution Solutions Grp I COM | $13.0M | 494.6K | 0.8% | ▲+50% Added · +165K sh | |
| 46 | Agomab Therapeutics NV SPONSORED ADS | $12.9M | 1.20M | 0.8% | ▲New New position | |
| 47 | Helix Acquisition Corp III USD CL A ORD SHS | $12.7M | 1.25M | 0.8% | ▲New New position | |
| 48 | Apyx Medical Corporation COM | $12.7M | 3.44M | 0.8% | ▼−13% Reduced · −534K sh | |
| 49 | Silence Therapeutics PLC ADS | $11.3M | 2.15M | 0.7% | ▲+39% Added · +604K sh | |
| 50 | Janux Therapeutics Inc COM | $11.3M | 809.9K | 0.7% | ▲New New position |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | ISHARES RUSSELL 2000 ETFIWM | $508.4M | 2.0M |
| CALL · bullish | HERBALIFE LTDHLF | $82.4M | 5.6M |
| CALL · bullish | PELOTON INTERACTIVE INC-APTON | $77.0M | 17.9M |
| CALL · bullish | VIATRIS INCVTRS | $67.5M | 5.0M |
| PUT · bearish | EDWARDS LIFESCIENCES CORPEW | $64.1M | 800K |
| CALL · bullish | TEVA PHARMACEUTICAL-SP ADRTEVA | $45.2M | 1.5M |
| CALL · bullish | UNIQURE NVQURE | $42.5M | 2.6M |
| CALL · bullish | HILTON GRAND VACATIONS INCHGV | $42.1M | 1.1M |
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $38.3M | 300K |
| CALL · bullish | REGENERON PHARMACEUTICALSREGN | $30.9M | 40K |
| CALL · bullish | SOLENO THERAPEUTICS INC | $25.1M | 750K |
| CALL · bullish | ALIGN TECHNOLOGY INCALGN | $17.1M | 100K |
| CALL · bullish | CAMPING WORLD HOLDINGS INC-ACWH | $13.7M | 2.0M |
| CALL · bullish | FOX FACTORY HOLDING CORPFOXF | $13.2M | 800K |
| CALL · bullish | RIDENOW GROUP INCRDNW | $12.0M | 1.7M |
| CALL · bullish | CHIME FINANCIAL INC-CL ACHYM | $11.2M | 600K |
| CALL · bullish | RHRH | $7.0M | 50K |
| CALL · bullish | BANCORP INC/THETBBK | $6.8M | 126K |
| CALL · bullish | ABEONA THERAPEUTICS INCABEO | $4.6M | 1.0M |
| PUT · bearish | DISC MEDICINE INCIRON | $2.6M | 41K |
| CALL · bullish | VAXCYTE INCPCVX | $2.0M | 35K |
| CALL · bullish | TELA BIO INCTELA | $465K | 750K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 152 | $2.7B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 153 | $3.0B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 153 | $2.9B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 158 | $2.6B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 145 | $2.5B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 137 | $2.3B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 140 | $2.0B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 20, 2024 | 130 | $1.7B | 13F-HR/A |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 124 | $1.8B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 15, 2024 | 128 | $1.7B | 13F-HR/A |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 133 | $1.2B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 124 | $1.0B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 124 | $1.3B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 118 | $1.5B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 10, 2022 | 120 | $1.5B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 124 | $2.0B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 13, 2022 | 122 | $2.3B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 136 | $2.8B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 130 | $3.2B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 121 | $3.5B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 116 | $3.4B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 126 | $3.2B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.